2019 saw tremendous growth for twoXAR. We launched nine new disease areas, expanding to new disease programs in our focus areas of ophthalmology, immunology & inflammatory, oncology and metabolic. We ended the year with eighteen total diseases in our portfolio, six of which have been out licensed.

Many believe AI is the panacea that will revolutionize the healthcare industry, and dollars are flowing into healthcare AI startups at unprecedented rates as investors make big bets on using the technology to analyze health data, improve efficiency in healthcare delivery, speed drug discovery, and offer new therapies for intractable diseases.

In the last several months, SKBP has achieved several remarkable drug development milestones, including the first FDA approval of an SKBP-discovered drug (Sunosi™, for excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea, which has been licensed to Jazz Pharmaceuticals) and FDA acceptance of their NDA submission for cenobamate, an investigational antiepileptic drug.

Researching new drug candidates in neurology with Ono represents a return to our roots at twoXAR. With Ono’s global history of drug development, we are confident we have found the right industry partner to work with.